Ghetti, G., Porta, C. and Povero, M. (2025) “Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”, Farmeconomia. Health economics and therapeutic pathways, 26(1). doi: 10.7175/fe.v26i1.1574.